- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dapagliflozin: A Review in Type 1 Diabetes ; volume:79 ; number:17 ; day:29 ; month:10 ; year:2019 ; pages:1877-1884 ; date:11.2019
Drugs ; 79, Heft 17 (29.10.2019), 1877-1884, 11.2019
- Creator
-
Paik, Julia
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-019-01213-x
- URN
-
urn:nbn:de:101:1-2020032301203828396981
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Paik, Julia
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Correction to: Dapagliflozin: A Review in Type 1 Diabetes
Correction to: Dapagliflozin: A Review in Type 2 Diabetes
P62 Dapagliflozin Preserves Renal Vasodilating Capacity in Hypertensive Patients with Type 2 Diabetes
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Dapagliflozin
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure
Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Typ-2-Diabetes – Dapagliflozin: Erfahrungen mit einer neuen Wirkstoffklasse
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy
Correction to: Dapagliflozin: A Review in Type 1 Diabetes
Correction to: Dapagliflozin: A Review in Type 2 Diabetes
P62 Dapagliflozin Preserves Renal Vasodilating Capacity in Hypertensive Patients with Type 2 Diabetes
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Dapagliflozin
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure
Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Typ-2-Diabetes – Dapagliflozin: Erfahrungen mit einer neuen Wirkstoffklasse
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy
Correction to: Dapagliflozin: A Review in Type 1 Diabetes
Correction to: Dapagliflozin: A Review in Type 2 Diabetes
P62 Dapagliflozin Preserves Renal Vasodilating Capacity in Hypertensive Patients with Type 2 Diabetes
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Dapagliflozin
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure
Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Typ-2-Diabetes – Dapagliflozin: Erfahrungen mit einer neuen Wirkstoffklasse
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment